Ikena Oncology, Inc.

NasdaqGM:IKNA Stock Report

Market Cap: US$66.1m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Ikena Oncology Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mark Manfredi

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage47.33%
CEO tenure7.6yrs
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure4.7yrs

Recent management updates

Analysis Article • Jun 01

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Key Insights Ikena Oncology to hold its Annual General Meeting on 7th of June Salary of US$569.0k is part of CEO Mark...

Recent updates

Analysis Article • Jun 01

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Key Insights Ikena Oncology to hold its Annual General Meeting on 7th of June Salary of US$569.0k is part of CEO Mark...
Analysis Article • Nov 10

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Aug 15

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Today is shaping up negative for Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders, with the analysts delivering a...
Analysis Article • May 20

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Shareholders in Ikena Oncology, Inc. ( NASDAQ:IKNA ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Apr 29

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 06

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 06

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 23

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Mar 21

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Ikena Oncology, Inc. ( NASDAQ:IKNA ) just released its annual report and things are looking bullish. The results were...
Analysis Article • Feb 19

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 02

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 13

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO Compensation Analysis

How has Mark Manfredi's remuneration changed compared to Ikena Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$31m

Mar 31 2025n/an/a

-US$42m

Dec 31 2024US$1mUS$569k

-US$49m

Sep 30 2024n/an/a

-US$60m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$70m

Dec 31 2023US$1mUS$569k

-US$68m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$546k

-US$69m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$5mUS$530k

-US$34m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$606kUS$410k

-US$44m

Compensation vs Market: Mark's total compensation ($USD1.20M) is above average for companies of similar size in the US market ($USD640.06K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Manfredi (53 yo)

7.6yrs
Tenure
US$1,202,210
Compensation

Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Manfredi
President7.6yrsUS$1.20mno data
Jotin Marango
COO, CFO3.3yrsUS$1.51m0%
$ 0
Rebecca Cohen
Senior VP of Investor Relations1.2yrsno datano data
Jeffrey Ecsedy
Chief Development Officer3.7yrsno datano data
Bob Lally
Senior Vice President of Finance & Operationsno datano datano data
David Damphousse
Senior Vice President of Clinical Development Operations1.8yrsno datano data
3.3yrs
Average Tenure
53yo
Average Age

Experienced Management: IKNA's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Manfredi
President7.6yrsUS$1.20mno data
Jean-Francois Formela
Independent Director9.3yrsUS$70.84k0%
$ 0
George Demetri
Chair of Scientific Advisory Board4.7yrsno datano data
Otello Stampacchia
Independent Director4.6yrsUS$66.34k0%
$ 0
Neal Rosen
Member of Scientific Advisory Boardno datano datano data
Kevan Shokat
Member of Scientific Advisory Board4.7yrsno datano data
Owen Hughes
Independent Chairman of the Board2.6yrsUS$108.34k0%
$ 0
David Bonita
Independent Director9.3yrsUS$72.34k0%
$ 0
Iain Dukes
Independent Director8.7yrsUS$69.84k0%
$ 0
Richard Wooster
Independent Director3.5yrsUS$58.34k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board4.7yrsno datano data
Maria Koehler
Independent Director4.3yrsUS$58.34k0%
$ 0
4.7yrs
Average Tenure
63yo
Average Age

Experienced Board: IKNA's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/25 06:59
End of Day Share Price 2025/07/25 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ikena Oncology, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David NierengartenWedbush Securities Inc.
Matthew PhippsWilliam Blair & Company L.L.C.